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Abstract
Objective
We assessed the associations of percentage fractions of urinary di(2-ethylhexyl) phthalate
(DEHP) metabolites with obesity and insulin resistance in Korean girls.
Methods
In total, 137 girls, aged 6 to 13 years (65 overweight cases and 72 controls), were recruited.
Anthropometric indices and the homeostatic model assessment of insulin resistance
(HOMA-IR) index were determined. Four major urinary DEHP metabolites were analyzed in
spot urine samples by gas chromatography-tandem mass spectrometry, including mono(2-
ethylhexyl) phthalate, mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono(2-ethyl-5-
oxohexyl) phthalate (MEOHP), and mono(2-ethyl-5-carboxypentyl) phthalate.
Results
There were no significant differences in the urinary concentrations of the DEHP metabolites
between the overweight and control groups. The percentage fraction of MEHHP (MEHHP
%) among all DEHP metabolites was significantly higher in the overweight prepubertal girls
than in the controls (P = 0.035). MEHHP% was positively associated with the body mass
index percentile, waist circumference, body fat percentage, and HOMA-IR index in the pre-
pubertal girls. After adjusting for covariates, the prepubertal girls in a higher MEHHP% quar-
tile were found to have a higher odds ratio for central obesity than those in a lower quartile
(odds ratios: 5.05 for quartile 3; 7.30 for quartile 4). The relative rate of MEHHP oxidation
to MEOHP was negatively associated with the body mass index percentile and waist
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circumference in the prepubertal girls. However, no such association was observed in the
pubertal girls.
Conclusions
MEHHP% was positively associated with obesity and insulin resistance in prepubertal girls.
Further studies are necessary to elucidate the causal links between altered phthalate
metabolism and increased susceptibility to insulin resistance in children.
Introduction
Phthalates are 1,2-benzenedicarboxylic acid esters used as plasticizers to make plastics more
flexible and soft and as vehicles in cosmetics [1]. They are found in various consumer prod-
ucts, including food packaging, toys, medical devices, building materials, and cosmetics [1].
Human exposure to phthalates occurs primarily through ingestion of contaminated food and
water, as well as through dermal contact and air inhalation. One of the types of phthalates
most frequently used in consumer products, di(2-ethylhexyl) phthalate (DEHP), is found at
relatively high concentrations in human specimens including blood, urine, breast milk, and
feces, and its metabolism has been widely studied [2]. The metabolic pathway of DEHP
involves a series of chemical reactions that produce various metabolites [3]. Following expo-
sure, DEHP is rapidly hydrolyzed by esterases in the gut, liver, and blood into mono(2-ethyl-
hexyl) phthalate (MEHP), which is subsequently metabolized by hepatic and intestinal
cytochrome P450 (CYP) enzymes into various secondary oxidative metabolites. Those second-
ary oxidative metabolites include mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono
(2-ethyl-5-oxohexyl) phthalate (MEOHP), and mono(2-ethyl-5-carboxypentyl) phthalate
(MECPP) (Fig 1). In human oral exposure study, approximately 75% of the DEHP dose was
excreted in urine in the form of the DEHP metabolites after 44 hours [3]. Therefore, the mea-
sured urinary concentrations of the oxidative DEHP metabolites are commonly used as bio-
markers of exposure to DEHP [1, 3].
It has been suggested that phthalates are obesogens and may induce obesity and metabolic
derangement [1]. This hypothesis has been supported by previous animal studies showing that
phthalate exposure increases body weight and insulin resistance [4–6]. Insulin resistance is
defined as an impairment in the ability of peripheral tissues to take up and utilize glucose in
response to insulin action, which leads to hyperinsulinemia. Insulin resistance is strongly asso-
ciated with central (visceral) obesity and an increased risk of metabolic syndrome and type 2
diabetes. The possible mechanisms of the development of obesity/insulin resistance upon
phthalate exposure have been suggested as follows: activation of peroxisome proliferator-acti-
vated receptors, inhibition of thyroid hormone and androgens, and direct interference with
the expression of the insulin receptor gene [7].
In recent decades, the relationship between DEHP exposure and obesity/insulin resistance
has been investigated in human studies [8–13]. However, the results of these studies have been
inconsistent and depended on the subjects’ demographic characteristics. Two U.S. epidemio-
logical studies based on the National Health and Nutrition Examination Survey data have
demonstrated positive associations of urinary DEHP metabolite concentrations with waist cir-
cumference (WC) and obesity in U.S. adults [8, 12], whereas another study reported a negative
association between the concentration of a specific urinary DEHP metabolites and the body
mass index (BMI) in U.S. elderly women [9]. Regarding the insulin resistance, one previous
Percentage fractions of DEHP metabolites and insulin resistance
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study did not find any significant relationship of urinary DEHP metabolite concentrations
with the homeostasis model assessment of insulin resistance (HOMA-IR) index in U.S. adult
men [12], whereas more recent studies have found positive associations in U.S. adults [10],
Belgian adults with obesity [13], and a Korean elderly population [11]. It has been suggested
that the vulnerability to phthalates in regard to insulin resistance may be different, depending
on ethnicity and gender; however, the possible mechanism has not yet been adequately
explained [9].
Previous studies have shown that percentage fractions of secondary metabolites of DEHP,
which may reflect the patterns of DEHP metabolism in organisms, differ, depending on the
species and age of laboratory animals [14, 15]. Similarly, in humans, the ratios of DEHP
metabolites have been reported to differ, depending on the subjects’ demographic factors. For
instance, higher ratios between MEHHP/MEOHP in European population were noted com-
pared with those in people from USA, Taiwan, and Israel [16]. The rate of MEHP-to-MEHHP
metabolic conversion in infants and children was reported to be faster than that in adults
[17, 18]. Therefore, we speculated that the inconsistent results of previous studies on the rela-
tionship between urinary DEHP metabolites and obesity/insulin resistance might be partly
explained by differences in the rate of DEHP metabolism.
In this study, we assessed whether the concentrations of individual DEHP metabolites and
their percentage fractions are related to obesity indices and insulin resistance in girls.
Subjects and methods
Subjects and study design
In total, of 65 overweight girls and 72 age-matched controls, aged 6–13 years, were recruited
from the Inje University Sanggye Paik Hospital (Seoul, Korea) between March 2015 and Sep-
tember 2015. The overweight girls were recruited from patients who visited the obesity clinic
to seek medical assessment. As controls, non-overweight girls were enrolled from those who
visited the pediatric health clinic for regular check-ups related to growth and development. All
eligible girls who attend the obesity clinic and pediatric health clinic during the study period
were asked whether they would like to participate in the study. The eligibility of the subjects
Fig 1. Metabolic pathway of di(2-ethylhexyl) phthalate (DEHP) metabolites. The relative rate of metabolism (RRM) was
calculated as the product-to-precursor molar concentration ratio as follows: RRM1 = ([MEHHP] + [MEOHP])/[MEHP]; RRM2 =
([MEOHP]/[MEHHP]) × 10; RRM3 = [MECPP]/[MEHP].
https://doi.org/10.1371/journal.pone.0208081.g001
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was identified before recruitment. All of the subjects recruited in this study were from Seoul,
the metropolitan city in South Korea. All participants voluntarily visited the hospital without
being referred from the local primary health care providers, devoid of a history of exposure to
Polyvinyl Chloride (PVC)- containing medical devices through intravenous procedures during
the previous one month. They were assessed via physical examination and history taking to
exclude underlying chronic diseases, endocrinopathies, and possible use of medications. Indi-
viduals who had been diagnosed with medical problems, including diabetes, thyroid disease,
hepatitis, familial hypercholesterolemia, or epilepsy requiring anticonvulsive therapy, were
excluded. The study protocol was approved by the Institutional Review Board of the Inje Uni-
versity Sanggye Paik Hospital (SGPAIK 2015-01-001-001), and written informed consent was
obtained from all subjects under age 18 and their parents before enrollment.
Anthropometric measurements and pubertal staging
The body weight and body fat percentage were measured using an InBody 720 body composi-
tion analyzer (Biospace Co., Ltd., Seoul, Korea), and the height was measured using a stadi-
ometer (Dongsahn Jenix Co., Seoul, Korea). The BMI (kg/m2) of each subject was calculated
based on these measures. The WC measurement was taken at the midpoint between the high-
est point of the iliac crest and the lowest point of the rib cage, at the end of a normal expiration,
with subjects standing in an upright position. Age- and gender-specific percentiles of the
height, weight, and BMI were calculated for each subject based on national reference charts
[19]. Overweight was defined as BMI� 85th percentile, and central obesity was defined as
WC� 90th percentile values for the age and gender.
Because insulin resistance increases in the pubertal period, sexual maturation of the breast
was determined in all subjects by a pediatric endocrinologist according to the Tanner staging
system [20]. The Tanner scale defines five sequential stages of sexual maturation, from prepu-
berty (stage 1) to adulthood (stage 5). Stage 2 indicates the onset of secondary sexual develop-
ment and the beginning of puberty; therefore, subjects who had reached at least stage 2 of
breast development were grouped as pubertal girls, whereas those who had not reached this
stage were classified as prepubertal girls.
Analysis of urinary DEHP metabolites
First morning spot urine samples were collected in polyethylene cups following a 10-h over-
night fast and stored at −80 ˚C until analysis. The sample preparation methods were described
elsewhere [18]. Four DEHP metabolites (MEHP, MEHHP, MEOHP, and MECPP) were ana-
lyzed by gas chromatography-tandem mass spectrometry using a 7890A gas chromatograph
and 7000 triple quadrupole mass spectrometer (Agilent, Palo Alto, CA, USA), with preceding
enzymatic deconjugation, followed by liquid-liquid extraction. In brief, isotope-labeled inter-
nal standards mixture was spiked into the urine sample. The spiked sample was then buffered
with ammonium acetate (1 M, pH = 6.0) and enzymatically hydrolyzed with E-coli β-glucuron-
idase at 37 ˚C for 2 h. Deconjugated sample was then buffered with 2 M acetic acid at pH 4.0–
4.5 followed by liquid-liquid extraction with hexane-ether solvents (8:2, v/v). The mixture was
centrifuged, and the organic phase was separated with freezer, concentrated under nitrogen
and dehydrated in vacuum desiccators. Trimethylsilyl derivatization was employed with
BSFTA/TMCS (99: 1, v/v) at 65 ˚C for 30 min and resulting derivatives were analyzed by gas
chromatography-tandem mass spectrometry using isotope dilution. We evaluated recovery
and precision by spiking standard material in reagent water. When the spiked concentration
in the sample (n = 5) was 10 ppb, recovery and precision were in the range of 61.61%–100.11%
and 4.27%–6.53%, respectively. The pooled urine samples (n = 5) were analyzed for each batch
Percentage fractions of DEHP metabolites and insulin resistance
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to perform the internal quality assurance/quality control (QA/QC), and the precision ranged
from 4.76% to 16.32% for the DEHP metabolites studied. The limits of detection for MEHP,
MEHHP, MEOHP, and MECPP were 0.2, 0.5, 1.0, and 5.0 μg/L, respectively. Detailed analyti-
cal method was provided in S1 Fig.
We presented the urine concentrations of DEHP metabolites in three forms, before correc-
tion (μg/L), urine creatinine-corrected concentrations (μg/g Cr), and urine specific gravity
(SG)-corrected concentrations (μg/L). A creatinine-corrected concentration is a value of the
measured urinary DEHP concentration (μg/L) divided by the urine creatinine level (g/L),
which is the most common method to adjust the urinary dilution in biomonitoring urinary
chemical concentrations. However, several physiological parameters including age, renal func-
tion, and muscle mass influence urine creatinine concentrations. Therefore, we also used the
SG-corrected concentrations, which is not influenced by age and muscle mass. The correction
formula is Pc = P x [(1.024–1)/(SG-1)], where Pc is the SG-corrected DEHP metabolite con-
centrations (μg/L), and P is the experimental DEHP metabolite concentrations [21].
Percentage fractions of the DEHP metabolites were calculated as a percentage ratio of the
molar concentration of a specific metabolite to the sum of the molar concentrations of all
DEHP metabolites. For example, MEHP% was determined as the ratio of [MEHP]/([MEHP]
+ [MEHHP] + [MEOHP] + [MECPP]) × 100. We also calculated the relative rate of metabo-
lism (RRM) to estimate the production rate of DEHP metabolites from their precursors.
RRMs were calculated as the product-to-precursor molar concentration ratios as follows:
RRM1, ([MEHHP] + [MEOHP])/[MEHP]; RRM2, ([MEOHP]/[MEHHP]) × 10; and RRM3,
[MECPP]/[MEHP] (Fig 1). Thus, RRM1 represents the rate of hydroxylation of MEHP to
MEHHP, whereas RRM2 and RRM3 represent the rates of oxidation from MEHHP to
MEOHP and from MEHP to MECPP, respectively.
Laboratory tests for insulin resistance
Blood samples were obtained on the day of urine sampling, following a 10-h overnight fast.
Plasma glucose levels were measured using an enzymatic assay (Pureauto S GLU; Daiichi,
Tokyo, Japan), and serum insulin levels were measured using an immunoradiometric assay
(INS-Irma; Biosource, Nivelles, Belgium). Insulin resistance in the subjects was estimated
using the HOMA-IR index, which is the most commonly used surrogate marker for insulin
resistance in children. HOMA-IR shows a good correlation with the hyperinsulinemic–eugly-
cemic clamp test, which is the gold standard for the measurement of insulin resistance. The
HOMA-IR index was calculated as fasting glucose (mg/dL) × fasting insulin (μU/mL)/405
[22].
Statistical analysis
Based on the study results of Wang et al. [21] on the DEHP metabolites concentrations of
between overweight and control groups, the sample size was calculated by setting the mean dif-
ferences of urinary MEHP levels (2.8 ng/mL), standard deviation (1.1), 5% level of significance,
and 95% statistical power. The concentrations of the phthalate metabolites and insulin, as well
as the HOMA-IR index, were log-transformed to improve the approximation of the normal
distribution. Data are shown as mean ± standard errors or number (%), unless otherwise indi-
cated. Data were analyzed using independent t-tests and chi-squared tests for continuous vari-
ables and discrete variables, respectively. Multiple linear regression was used to explore the
relationships between phthalate metabolite concentrations and obesity-related metabolic
parameters, after adjustment for age, Tanner stage, and height/BMI percentile. Estimated dif-
ferences in the means and 95% confidence interval (CI) were calculated using analysis of
Percentage fractions of DEHP metabolites and insulin resistance
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covariance to compare anthropometric data and metabolic parameters, including the
HOMA-IR index, with the MEHHP% quartile. The P-for-trend was obtained by linear regres-
sion modeling of the MEHHP% quartile as a continuous variable. Multiple logistic regression
analysis was performed to examine the odds ratio (OR) and 95% CI for central obesity across
the MEHHP% quartile, after adjusting for the age and height percentiles. Statistical analyses
were performed using PASW Statistics for Windows, version 18.0 (SPSS, Inc., Chicago, IL,
USA). Two-tailed P< 0.05 was considered statistically significant.
Results
The general characteristics of the subjects are summarized in Table 1. The mean ages of the
prepubertal and pubertal girls were 8.1 and 9.5 years, respectively. The overweight girls had a
significantly higher BMI, WC, body fat percentage, and HOMA-IR index than the prepubertal
and pubertal control girls.
The distributions of the urinary DEHP metabolites are presented in Table 2 and S2 Fig.
All metabolite concentrations were above the limits of detection. Among the DEHP urinary
metabolites, MECPP was detected at the highest concentration, followed by MEHHP,
MEOHP, and MEHP. The percentage fraction was also the highest for MECPP% (50.3%)
among the individual DEHP metabolites, followed by MEHHP% (22.5%), MEOHP% (17.9%),
and MEHP% (9.4%).
The concentrations and percentage fractions of the urinary DEHP metabolites are stratified
by the pubertal and obesity statuses in Table 3. There were no significant differences in the
urinary DEHP metabolite levels between the overweight and control girls, regardless of the
pubertal status. Among the prepubertal girls, a significantly higher MEHHP% was found in
the overweight girls than in the controls (Table 3 and S2 Fig), whereas MEHP%, MEOHP%,
and MECPP% were not significantly different depending on the obesity status. In the pubertal
girls, no significant differences were identified in the percentage fractions of the urinary
DEHP metabolites between the overweight and control groups.
Table 1. General characteristics of the study subjects by obesity and the puberty status.
Prepubertal girls Pubertal girls P-value (pubertal vs prepubertal girls)
Control Overweight P-value Control Overweight P-value
n = 35 n = 33 n = 37 n = 32
Age (years) 8.2 ± 0.1 8.0 ± 0.1 0.596 9.7 ± 0.2 9.3 ± 0.3 0.277 < 0.001
BMI (kg/m2) 16.5 ± 0.2 21.7 ± 0.3 < 0.001 16.8 ± 0.2 22.2 ± 0.4 < 0.001 0.580
BMI percentile 49.4 ± 4.0 95.8 ± 0.7 < 0.001 42.3 ± 3.3 94.8 ± 0.7 < 0.001 0.296
WC (cm) 59.5 ± 1.0 72.2 ± 1.1 < 0.001 61.9 ± 1.0 74.6 ± 1.5 < 0.001 0.353
WC percentile 61.2 ± 4.8 95.5 ± 0.8 < 0.001 53.9 ± 4.2 93.0 ± 1.9 < 0.001 0.158
Body fat (%) 21.1 ± 1.3 35.4 ± 0.8 < 0.001 22.9 ± 0.9 32.7 ± 1.5 < 0.001 0.544
Tanner stage 0.364 < 0.001
1 35 (100%) 33 (100%) 0 (0%) 0 (0%)
2 21 (56.8%) 13 (40.6%)
3 7 (18.9%) 12 (37.5%)
4 7 (18.9%) 5 (15.6%)
5 2 (5.4%) 2 (6.3%)
Fasting glucose (mg/dL) 92.4 ± 1.0 96.8 ± 1.1 0.007 92.7 ± 1.3 94.3 ± 1.6 0.468 0.379
Fasting insulin (μU/mL) 8.1 ± 0.7 12.9 ± 1.1 0.001 9.8 ± 0.8 17.0 ± 2.7 0.006 0.041
HOMA-IR 1.9 ± 0.1 3.1 ± 0.2 0.001 2.3 ± 0.1 3.8 ± 0.5 0.007 0.105
https://doi.org/10.1371/journal.pone.0208081.t001
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RRMs of the DEHP metabolites were stratified by the obesity and puberty status (S1 Table).
A significantly lower RRM2 was found in the overweight girls than in the controls, but only
for the prepubertal girls. No significant differences were found in RRM1 and RRM2, regardless
of obesity and puberty status.
Table 2. Geometric means (GM) and selective percentiles of urinary phthalate metabolite concentrations.
Phthalate metabolites Range GM Percentile
10th 25th 50th 75th 90th
Uncorrected concentrations (μg/L)
MEHP 0.3–54.0 11.1 6.3 7.7 10.2 15.7 23.2
MEHHP 4.2–378.9 31.8 9.9 16.1 33.6 57.5 95.0
MEOHP 4.7–194.8 25.5 9.1 13.5 24.9 45.7 69.4
MECPP 5.0–919.6 75.3 19.8 41.4 78.6 146 230
Specific gravity-corrected concentrations (μg/L)
MEHP 0.2–85.5 15.4 7.9 9.9 14.9 23.1 39.5
MEHHP 6.3–413.4 44.2 18.0 27.4 42.2 73.4 123
MEOHP 6.7–287.2 35.4 15.7 21.7 32.7 57.1 92.8
MECPP 14.3–1127.5 104 41.4 59.5 103 163 345
Creatinine-corrected concentrations (μg/g Cr)
MEHP 0.2–75.6 12.6 6.7 9.7 12.6 19.6 32.1
MEHHP 7.1–533 36.8 17.8 26.8 36.5 56.7 83.2
MEOHP 7.3–274 29.5 14.5 21.1 30.6 45.1 65.8
MECPP 18.8–940 87.3 37.3 55.5 90.8 140 206
https://doi.org/10.1371/journal.pone.0208081.t002
Table 3. Geometric means (± standard error) of urinary phthalate metabolite concentrations and percentage fractions of di(2-ethylhexyl) phthalate (DEHP) metab-
olites by obesity and puberty status.
Prepubertal girls Pubertal girls P-value (pubertal vs prepubertal girls
Control Overweight P-value Control Overweight P-value
n = 35 n = 33 n = 37 n = 32
Uncorrected concentrations (μg/L)
MEHP 13.9 ± 1.7 12.9 ± 1.6 0.679 14.1 ± 1.4 10.9 ± 0.7 0.058 0.562
MEHHP 44.7 ± 6.4 49.3 ± 11.7 0.732 47.8 ± 6.2 44.8 ± 10.3 0.801 0.947
MEOHP 36.6 ± 5.1 34.6 ± 6.5 0.805 37.5 ± 5.0 31.6 ± 5.6 0.435 0.876
MECPP 121.6 ± 119.7 ± 26.1 0.950 121.4 ± 20.3 111.0 ± 27.9 0.761 0.867
Specific gravity-corrected concentrations (μg/L)
MEHP 20.3 ± 2.7 19.6 ± 3.0 0.854 20.4 ± 2.1 15.8 ± 1.5 0.089 0.489
MEHHP 55.2 ± 7.2 66.0 ± 15.9 0.529 63.0 ± 7.1 54.7 ± 10.2 0.494 0.905
MEOHP 45.8 ± 5.6 48.1 ± 58.1 0.843 50.1 ± 5.8 40.6 ± 5.9 0.261 0.861
MECPP 144.4 ± 21.6 159.6 ± 40.5 0.737 161.5 ± 23.1 136.1 ± 28.4 0.486 0.944
Creatinine-corrected concentrations (μg/g Cr)
MEHP 15.2 ± 2.5 14.0 ± 2.9 0.848 11.9 ± 1.4 13.2 ± 1.5 0.913 0.080
MEHHP 41.5 ± 5.6 38.3 ± 15.6 0.941 37.7 ± 4.3 37.7 ± 5.8 0.994 0.350
MEOHP 35.0 ± 4.5 29.7 ± 8.1 0.640 30.3 ± 3.5 29.7 ± 3.4 0.741 0.243
MECPP 104.1 ± 1.7 82.8 ± 29.3 0.989 90.3 ± 14.4 90.9 ± 15.6 0.895 0.413
% of DEHP metabolites (based on molarity)
MEHP% 9.4 ± 0.9 10.2 ± 1.1 0.560 8.6 ± 0.6 9.4 ± 0.9 0.435 0.360
MEHHP% 21.5 ± 0.5 23.5 ± 0.8 0.035 22.7 ± 0.5 22.4 ± 0.5 0.687 0.839
MEOHP% 17.9 ± 0.5 18.0 ± 0.6 0.916 17.9 ± 0.3 17.5 ± 0.4 0.433 0.600
MECPP% 51.2 ± 1.6 48.3 ± 1.8 0.249 50.8 ± 0.9 50.7 ± 1.1 0.948 0.500
https://doi.org/10.1371/journal.pone.0208081.t003
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After controlling for the age and height percentiles, MEHHP% was positively associated
with the BMI percentile, WC, and body fat percentage in the prepubertal girls (Table 4 and Fig
2). The adjusted ORs for central obesity increased for higher MEHHP% quartiles and were
5.05 for quartile 3 and 7.30 for quartile 4 (Fig 3). In the pubertal girls, however, no significant
associations were found between the percentage fractions of the DEHP metabolites and
anthropometric indices. RRM2 showed a significant negative association with the BMI percen-
tile and WC in the prepubertal girls (S2 Table). In the pubertal girls, no significant associations
were found between RRMs of the DEHP metabolites and obesity indices.
The HOMA-IR indexes were positively associated with MEHHP% in the prepubertal girls,
even after adjusting for the age and obesity status (Fig 4). Additionally, the urinary concentra-
tions of the individual DEHP metabolites showed no significant associations with anthropo-
metric indices or insulin resistance markers, regardless of puberty status (data not shown).
Table 4. Regression analysis of associations between percentage fractions of di(2-ethylhexyl) phthalate (DEHP)
metabolites and anthropometric indices (adjusted for age, Tanner stage, and height percentile, �P< 0.05).
BMI percentile WC (cm) Body fat (%)
β (95% CI) β (95% CI) β (95% CI)
Prepubertal girls
MEHP% 0.65 (−0.56 to 1.85) 0.09 (−0.29 to 0.46) −0.01(−0.42 to 0.40)
MEHHP% 1.93 (0.18 to 3.70)� 0.67 (0.15 to 1.19)� 0.60 (0.03 to 1.18)�
MEOHP% 0.23 (−1.98 to 2.44) 0.20 (−0.47 to 0.88) 0.21 (−0.52 to 0.94)
MECPP% −0.53 (−1.21 to 0.16) −0.52 (−0.09 to 0.56) −1.11 (−0.34 to 1.12)
Pubertal girls
MEHP% 0.50 (−0.45 to 1.47) 0.06 (−0.24 to 0.37) −0.05 (−0.35 to 0.25)
MEHHP% 0.69 (−0.71 to 2.09) 0.37 (−0.06 to 0.80) 0.34 (−0.33 to 1.00)
MEOHP% −0.36 (−2.17 to 1.45) −0.11 (−0.68 to 0.45) −0.08 (−0.48 to 0.63)
MECPP% −0.28 (−0.88 to 0.31) −0.08 (−0.27 to 0.10) −0.08 (−0.27 to 0.10)
https://doi.org/10.1371/journal.pone.0208081.t004
Fig 2. Estimated differences in the means and 95% confidence intervals of the body mass index (BMI) percentile and waist
circumference (WC) stratified by the percentage fraction of mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP%) quartiles in
prepubertal girls (adjusted for age and height percentiles). For higher MEHHP% quartiles, the BMI percentile and WC increased
in prepubertal girls (P-for-trend< 0.05).
https://doi.org/10.1371/journal.pone.0208081.g002
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Discussion
In this study, we found that obese prepubertal girls showed higher MEHHP% and lowered
RRM2, suggesting an impaired rate of MEHHP-to-MEOHP metabolic conversion. MEHHP%
in prepubertal girls was positively associated with obesity markers, including BMI percentile,
WC, and the body fat percentage. Furthermore, MEHHP% positively correlated with insulin
resistance in prepubertal girls even after adjusting for obesity status. To the best of our knowl-
edge, this study is the first to show a positive correlation between MEHHP% and an insulin
resistance marker (HOMA-IR index) in children.
In our study, the concentrations of individual DEHP metabolites and their total concentra-
tion did not show significant relationships with obesity parameters in the girls, which is consis-
tent with the results of a large-scale cross-sectional study that used the National Health
and Nutrition Examination Survey [23] and a prospective cohort study of New York City
children [24]. Emerging evidence suggests that DEHP exposure, estimated by urinary DEHP
Fig 3. Adjusted odds ratios (ORs) and 95% confidence intervals for central obesity in prepubertal girls, stratified by percent
fractions of mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP%) quartiles (adjusted for age and height percentiles). The
adjusted OR for central obesity significantly increased for higher MEHHP% quartiles (P-for-trend = 0.014).
https://doi.org/10.1371/journal.pone.0208081.g003
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concentrations, may be linked to obesity in children, but the results are inconsistent [23–25].
A positive correlation between BMI and the urinary MEHHP has been reported in prepubertal
Chinese boys [21, 25], whereas an inverse correlation has been observed in prepubertal Chi-
nese girls [25]. One study has shown a negative correlation between the urinary MECPP con-
centration and BMI in Danish children younger than 10 years old [26], although positive
correlations have been reported between the urinary MECPP concentrations and increased
BMI and WC in prepubertal and pubertal Italian children [27]. It is unclear why the associa-
tions between DEHP metabolite concentrations and childhood obesity are not consistent and
depend on these demographic characteristics. One possible explanation is that these character-
istics may lead to differences in the pharmacokinetics of DEHP. DEHP is metabolized in
humans and laboratory animals by CYP enzymes, and previous studies have suggested that the
rate of metabolism is determined by individual-specific differences in CYP enzyme activities
in the liver and intestine [14, 15, 28, 29]. Furthermore, a recent in vitro study has indicated
Fig 4. Estimated differences in the means and 95% confidence intervals of the homeostatic model assessment of insulin
resistance (HOMA-IR) index stratified by quartiles of percentage fractions of mono(2-ethyl-5-hydroxyhexyl) phthalate
(MEHHP%) in prepubertal girls (adjusted for age and obesity status). Prepubertal girls in the highest quartile of MEHHP% had
significantly higher HOMA-IR indexes compared with those in the lowest quartile (P = 0.035).
https://doi.org/10.1371/journal.pone.0208081.g004
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that human hepatic CYP2C9 is the principal isoform involved in the production of MEHP-
derived metabolites, and the substrate specificity and catalytic activity of CYP2C9 differ,
depending on genetic variations [28, 30, 31]. A recent study has shown that the MEHHP/
MEOHP ratios of human population widely varies by race/ethnicity from the different geo-
graphical areas [16]. Therefore, genetic differences in the capacity to metabolize DEHP might
partly explain the different relationships between urinary DEHP metabolites and obesity/insu-
lin resistance in previous human studies.
Some previous studies have demonstrated positive associations between MEHP% and BMI
in children and adult populations [26, 32]. Regarding the insulin resistance, a few studies have
demonstrated that increased urinary DEHP metabolite concentrations were linked to insulin
resistance in adults [10, 11, 13] and children [33]. However, the associations between percent-
age fractions of individual DEHP metabolites and anthropometric measures/insulin resistance
markers have not been thoroughly investigated yet. We found that MEHHP% was positively
correlated with the BMI percentile, WC, and body fat percentage in prepubertal obese girls.
Furthermore, MEHHP% was related to the HOMA-IR index in prepubertal obese girls, even
after adjusting for the obesity status. Of note, previous studies have revealed that endocrine-
disrupting effects and toxicities of individual DEHP metabolites are not identical. MEHHP has
been reported as a potential activator of peroxisomal enzymes [34] and an anti-androgen [35]
in in vitro studies, which have not identified endocrine-disrupting effects of MECPP. Thus,
our findings, along with previous studies, suggest that patterns of DEHP metabolism among
individuals may be an essential determinant of health impact after DEHP exposure. We sug-
gest that in studies on the associations between EDC exposure and health outcome, the meta-
bolic rate of the EDCs need to be considered, mainly when the target EDCs are metabolized
into multiple metabolites in the body. However, given the cross-sectional nature of this study,
we could not determine a causal relationship between the decreased rate of MEHHP metabo-
lism and the occurrence of obesity/insulin resistance.
We observed puberty-related differences in the correlations between percentage fractions
of DEHP metabolites and metabolic parameters in this study. This finding may be related to
the endogenous estrogen status and subsequent changes in CYP enzymatic activity [36]. Ani-
mal studies have demonstrated that female hormones, including estradiol and progesterone,
may influence the rate of drug metabolism by changing hepatic CYP expression [37, 38]. Fur-
thermore, the results of a recent experimental study suggested that estradiol may change the
enzyme activity of human hepatic CYP2C9 [39], which could partly explain the differences in
the association between DEHP metabolism and obesity related to puberty status or age. How-
ever, because this was a cross-sectional study that included only Korean girls, the impact of
puberty on the relationship between obesity and DEHP metabolism is still an open question.
Our study had a few limitations. First, we did not assess dietary patterns and calorie intakes
in the study subjects. Second, the cross-sectional design of the study limited the inference of
causality. Third, we used single-spot urine samples to measure urinary DEHP metabolites.
Nonetheless, this is the first attempt to correlate the percentage fractions of individual DEHP
metabolites with central obesity and insulin resistance in children. Furthermore, we demon-
strated a significant relationship between MEHHP% and insulin resistance/central obesity in
prepubertal girls, even after controlling for the age and obesity status.
Conclusions
In conclusion, a higher MEHHP% and lower molar concentration ratio of MEOHP/MEHHP
were associated with obesity and insulin resistance in prepubertal girls. However, it remains
unclear whether impaired MEHHP-to-MEOHP metabolism is a cause or consequence of
Percentage fractions of DEHP metabolites and insulin resistance
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childhood obesity and insulin resistance. The potential causal links between the relative rates
of DEHP metabolism and metabolic perturbations in children require further investigation.
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